Cell Therapy News/Articles, page-5210

Most of us who keep an eye on MSB’s progress would be aware of many Covid-19 related clinical trials currently underway.

A recently released research paper has put them into perspective.

As at May 19th, 2020, the researchers found 1551 Covid-19 related trials registered on clinicaltrials.gov. On the surface that represents huge opposition. But of those, only 664 were randomised clinical trials. And of those 664, only 11.3% (or about 75) were placebo controlled, blinded and had at least 2 study centres.

MSB's Covid-19 ARDS trial is placebo controlled, double blinded with about 15 study centres and about 30 sites.

And of course, many of the other trials are aimed at a different target subgroup, so there’s clearly very limited competition.

The researchers concluded:
"Even before results are known, most studies likely will not yield meaningful scientific evidence at a time when rapid generation of high-quality knowledge is critical."

I’m reassured and very comfortable with that assessment. Positive support for MSB's trial design imo. Bring on results that give the FDA an easy choice.

https://medicalxpress.com/news/2020-07-large-proportion-covid-low-level-evidence.html